Company intelligence / Profile preview
Ventrus Biosciences, Inc.
New York, New York, United Statesassemblybio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ventrus completed clinical development of VEN 307 and had scheduled a meeting with the FDA on June 19, 2014, to discuss filing an NDA[5][7].
- Therapeutic areas
- GastroenterologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Ventrus Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ventrus Biosciences, Inc..